Half-year report · Q2
4626.TEDINET S100UMJG
Period2024-04-01 → 2024-09-30
Filed2024-11-06
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥59.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥104.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥51.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥12.4bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥9.1bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥12.4bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥17.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.7bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥12.4bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥8.7bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥9.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥8.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.2bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥9.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥6.2bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥206.8bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥212.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥197.9bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥100.8bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥112.4bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥106.1bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥100.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥99.6bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥53.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥58.6bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥53.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥57.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥45.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥47.1bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥12.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥21.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥21.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥11.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥9.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥164.52 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.89 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥111.64 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 51.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.3% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥2.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥2.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥195m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥138m |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥42.6bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥42.6bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥12.0bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.1bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.1bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥931m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥57.6bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥57.6bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥13.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥60.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥59.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥195m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥148m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥74m |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥34.7bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥34.7bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥14.6bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥14.6bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.7bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥49.3bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥49.3bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥9.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥51.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥51.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥148m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥9.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 494
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | 21500000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -6201000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -28254000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -0 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -92000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -2902000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -2354000000 | JPY |
| Proceeds from issuance of common stock fin cf | Prior1YTDDuration | 164000000 | JPY |
| Proceeds from issuance of common stock fin cf | CurrentYTDDuration | 129000000 | JPY |
| Other net fin cf | Prior1YTDDuration | -140000000 | JPY |
| Other net fin cf | CurrentYTDDuration | -154000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -1019000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -11360000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 942000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | -331000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -1734000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -4698000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 47088000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 57664000000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | Prior1YTDDuration | － | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | CurrentYTDDuration | 341000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 45353000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 53306000000 | JPY |
| Trade notes receivable transferred by endorsement | Prior1YearInstant | 1155000000 | JPY |
| Trade notes receivable transferred by endorsement | CurrentQuarterInstant | 1721000000 | JPY |
| Salaries sga | Prior1YTDDuration | 2347000000 | JPY |
| Salaries sga | CurrentYTDDuration | 2727000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 436000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 669000000 | JPY |
| Provision for directors bonuses sga | Prior1YTDDuration | 222000000 | JPY |
| Provision for directors bonuses sga | CurrentYTDDuration | 285000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 131000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 139000000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | -18000000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | -32000000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 2438000000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 3296000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00913-000ElectronicsMaterialsReportableSegmentsMember | 34729000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00913-000MedicalAndPharmaceuticalsReportableSegmentsMember | 14609000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 49339000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1768000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 51107000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00913-000ElectronicsMaterialsReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00913-000MedicalAndPharmaceuticalsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 148000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 148000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00913-000ElectronicsMaterialsReportableSegmentsMember | 34729000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00913-000MedicalAndPharmaceuticalsReportableSegmentsMember | 14609000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 49339000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |